Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry.
BACKGROUND
Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) may be useful in patients with acute myocardial infarction (AMI), but safety issues still need to be solved. This study was undertaken to investigate the incidence of major adverse cardiac events (MACE) and stent thrombosis in DES-implanted AMI patients in real-life clinical practice.


RESULTS
On-line registry of AMI cases at the web site www.kamir.or.kr has been performed in 41 primary PCI centers in Korea and between November 2005 and September 2006, 1,541 surviving patients who had been implanted with either Cypher or Taxus stents were enrolled for analysis during a 6-month clinical follow-up. There were 2 groups: group I [834 patients, 61.9+/-11.9 years: sirolimus-eluting stent (Cypher)], group II [707 patients, 62.9+/-12.0 years: paclitaxel-eluting stent (Taxus)]. At both 1 and 6 months the incidence of MACE was not significantly different between the 2 groups. There were 17 cases of stent thrombosis, but the incidence of stent thrombosis was not significantly different between the 2 groups (group I:II=9 (1.1%):8 (1.1%), p=1.000). The stent type, length, number, lesion complexity and diabetes were not significant for the incidence of MACE or stent thrombosis after adjustment.


CONCLUSIONS
MACE and stent thrombosis rates did not differ between 2 types of DES identified in Korea Acute Myocardial Infarction Registry (KAMIR). DES can be used in patients with AMI with a relatively low 6-month MACE rate.
Lee
Sang Rok
SR
Chonbuk National University Research Institute of Medical Science, Jeonju, South Korea.
Jeong
Myung Ho
MH
Ahn
Young Keun
YK
Chae
Shung Chull
SC
Hur
Seung Ho
SH
Kim
Young Jo
YJ
Seong
In Whan
IW
Chae
Jei Keon
JK
Hong
Taek Jong
TJ
Rhew
Jae Young
JY
Cho
Myeong Chan
MC
Bae
Jang Ho
JH
Rha
Seung Woon
SW
Kim
Chong Jin
CJ
Jang
Yang Soo
YS
Park
Seung Jung
SJ
D000208:Acute Disease; D000368:Aged; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000209:etiology; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007723:Korea; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000208:ethnology / Q000503:physiopathology / Q000628:therapy*; D017239:Paclitaxel; D011446:Prospective Studies; D012042:Registries / Q000706:statistics & numerical data*; D012307:Risk Factors; D020123:Sirolimus; D016896:Treatment Outcome
D017239:Paclitaxel; D020123:Sirolimus